SCHEMBL26174488

SCHEMBL26174488

c1cnc2[nH]cc(-c3nc4cnccc4[nH]3)c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 4/20 0.58
▸ IKBKE Q14164 3/20 0.58
▸ PDPK1 O15530 3/20 0.58
▸ TBK1 Q9UHD2 3/20 0.54
▸ RHEB Q15382 1/20 0.49
▸ LATS1 O95835 1/20 0.48
▸ LATS2 Q9NRM7 1/20 0.48
▸ RPS6KA5 O75582 1/20 0.47
▸ CDK2 P24941 3/20 0.46
▸ CDK9 P50750 2/20 0.46
▸ CDK5 Q00535 2/20 0.46
▸ CCNT1 O60563 1/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CCNA1 P78396 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ CDC7 O00311 6/20 0.46
▸ DBF4 Q9UBU7 3/20 0.46
▸ DYRK1A Q13627 2/20 0.44
▸ PIM1 P11309 3/20 0.43
▸ MAP4K4 O95819 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16719855 0.81 RHEB (0.47) TGFBR1IKBKEPDPK1TBK1RHEB
SCHEMBL30874496 0.76 CDK1 (0.71) PDPK1RPS6KA5CDK2KDM4ENPC1
SCHEMBL29714866 0.76 CLK2 (0.50) TGFBR1PDPK1DYRK1AKDM4ECLK2
SCHEMBL17555908 0.76 CLK2 (0.50) TGFBR1PDPK1DYRK1AKDM4ECLK2
SCHEMBL8566063 0.74 ALDH1A1 (0.50) CDK2CDK5CDK5R1GSK3BKDM4E
SCHEMBL12501045 0.74 TGFBR1 (1.00) TGFBR1IKBKEPDPK1TBK1RPS6KA5
SCHEMBL5618155 0.74 TGFBR1 (0.71) TGFBR1IKBKEPDPK1TBK1RPS6KA5
SCHEMBL16572576 0.73 TGFBR1 (0.67) TGFBR1IKBKEPDPK1TBK1LATS1
SCHEMBL20466101 0.72 METAP2 (0.50) KDM4ENPC1ALDH1A1HPGDRAB9A
SCHEMBL857678 0.71 IKBKE (0.64) TGFBR1IKBKEPDPK1TBK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415817-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 — — US disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 — — US disclosed
WO-2023064349-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 TGFBR1 2134/4885IKBKE 746/4885PDPK1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback